Summary
The provided AI statements largely do not match the supplied FDA label excerpts, with multiple dosing/administration and food-interaction claims unsupported by the provided label sections for the thyroid C-cell tumor risk. As a result, overall alignment cannot be established for the requested labeling scope.
Category Scores
Accurate Statements
The supplied label excerpt contains a stated risk of thyroid C-cell tumors (rodents) and notes human relevance is unknown.
5.1 Risk of Thyroid C-Cell Tumors; 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility; 17 Patient Counseling Information
Unsupported Statements
Ozempic is used to treat type 2 diabetes.
No FDA label sections for indication were provided in the prompt; only thyroid C-cell tumor-related sections (4, 5.1, 13.1, 6, 17) were supplied.
Ozempic is approved for the treatment of obesity in adults.
No indication/label section for obesity was provided in the prompt.
Ozempic is a prescription medication approved by the US FDA in 2017 for the treatment of type 2 diabetes.
No approval date or diabetes indication approval history was provided in the prompt label excerpts.
Ozempic should be taken on an empty stomach.
No dosing/administration instructions were provided in the prompt label excerpts.
Ozempic should be taken at least 30 minutes before the first meal of the day.
No dosing timing instructions were provided in the prompt label excerpts.
Food can slow down the absorption of Ozempic.
No pharmacokinetics/food effect information was provided in the prompt label excerpts.
Food can slow down gastric emptying of Ozempic.
No gastric emptying statements were provided in the prompt label excerpts.
Slower gastric emptying may reduce Ozempic absorption and effectiveness.
No information connecting gastric emptying to absorption/effectiveness was provided in the prompt label excerpts.
The digestive process can break down Ozempic.
No information was provided in the prompt label excerpts about degradation in the GI tract for this product.
Breaking down Ozempic can reduce its potency and lead to reduced efficacy.
No information provided in the prompt label excerpts.
Certain nutrients, such as fiber and protein, can interact with Ozempic and affect its absorption.
No food/nutrient interaction information was provided in the prompt label excerpts.
High-fiber foods can slow down the gastric emptying of Ozempic and reduce its absorption.
No such food/nutrient interaction information was provided in the prompt label excerpts.
Protein-rich foods can slow down the gastric emptying of Ozempic.
No such food/nutrient interaction information was provided in the prompt label excerpts.
Fatty foods can slow down the digestion of Ozempic and reduce its effectiveness.
No such food/nutrient interaction information was provided in the prompt label excerpts.
Low-fiber foods may be easier to digest and may not slow down the gastric emptying of Ozempic.
No such food/nutrient interaction information was provided in the prompt label excerpts.
Low-protein foods may be easier to digest and may not slow down the gastric emptying of Ozempic.
No such food/nutrient interaction information was provided in the prompt label excerpts.
Lean protein sources, such as poultry and fish, may be easier to digest and may not slow down the gastric emptying of Ozempic.
No such food/nutrient interaction information was provided in the prompt label excerpts.
Ozempic should not be taken with a meal that contains a lot of fiber because it may slow down gastric emptying of the medication.
No such administration/food restriction information was provided in the prompt label excerpts.
Ozempic should not be taken with a meal that contains a lot of protein because it may slow down gastric emptying of the medication.
No such administration/food restriction information was provided in the prompt label excerpts.
Foods high in fiber, protein, and fat—such as bran, beans, cabbage, meat, fish, eggs, fried foods, and oils—should be avoided with Ozempic.
No food avoidance guidance was provided in the prompt label excerpts.
Foods low in fiber, protein, and fat—such as white bread, pasta, rice, fruits, and vegetables—can be eaten with Ozempic.
No food allowance guidance was provided in the prompt label excerpts.
Ozempic food impact is described as a complex issue requiring more research to fully understand effects of different foods on the medication.
No statements about complexity or need for more research regarding food effects were provided in the prompt label excerpts.
Contradictions
Important Omissions
If evaluating the requested thyroid C-cell tumor risk claim, the AI response should include specific label-consistent details such as contraindication in patients with personal/family history of MTC or MEN 2 and symptom counseling (neck mass, dysphagia, dyspnea, persistent hoarseness) and/or the statement that routine calcitonin/ultrasound monitoring value is uncertain.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple administration/food timing and restriction statements are unsupported by the provided label excerpts. In the context of an audit focused on on-label thyroid C-cell tumor risk information, these unsupported statements substantially reduce on-label fidelity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most AI statements are outside the supplied FDA label scope (thyroid C-cell tumor sections) and are unsupported by the provided prescribing information excerpts.
Suggested Improvement
Limit claims to the provided label sections (4, 5.1, 13.1, 6 referencing thyroid risk, and 17 counseling). For thyroid risk, explicitly state contraindications (personal/family history of MTC or MEN 2), the rodent findings with unknown human relevance, and the patient symptom counseling/monitoring uncertainty as described in 5.1/17.